

Publications 2013

PRAZUCK T, CHAILLON A, AVETTAND-FENOEL V, CAPLAN A-L, SAYANG C, GUIGON A, NIANG M, BARIN F, ROUZIOUX C, HOCQUELOUX L. HIV-DNA in the genital tract of women on long-term effective therapy is associated to residual viremia and previous AIDS-defining illness. **Plos One** 2013, 8, e69686.

BRAIBANT M, BARIN F. The role of neutralizing antibodies in prevention of HIV-1 infection : what can we learn from the mother-to-child transmission context ? **Retrovirology** 2013, 10 :103.

D'ARIENZO V, MOREAU A, D'ALTEROCHE L, GISSOT V, BLANCHARD E, GAUDY-GRAFFIN C, ROCH E, DUBOIS F, GIRAudeau C, PLANTIER JC, GOUDEAU A, ROINGEARD P, BRAND D. Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host. **J Virol** 2013, 87, 13609-13618.

KHAMDUANG W, GAUDY-GRAFFIN C, NGO-GIANG-HUONG N, JOURDAIN G, MOREAU A, BORKIRD T, LAYANGOOL P, KAMONPAKORN N, JITPHIANKHA W, KWANCHAIPANICH R, POTCHALONGSIN S, LALLEMANT M, SIRIRUNGSI W, GOUDEAU A and the Program for HIV Prevention and Treatment (PHPT) group. Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring. **J Clin Virol**, 2013, 58(2), 415-21.

ROINGEARD P. Hepatitis C virus diversity and liver steatosis. **J Viral Hepat** 2013, 20, 77-84.

BEAUMONT E, PATIENT R, HOURIOUX C, DIMIER-POISSON I, ROINGEARD P. Chimeric HBV-HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent HBV-HCV prophylactic vaccine. **Hepatology** 2013, 57, 1303-1313.

FERRARIS P, BEAUMONT E, UZBEKOV R, BRAND D, GAILLARD J, BLANCHARD E, ROINGEARD P. Sequential biogenesis of host cell membrane rearrangements induced by hepatitis C virus infection. **Cell Mol Life Sci** 2013, 70, 1297-1306.

VIEYRES G, BROHM C, FRIESLAND M, GENTZCH J, WOLK B, ROINGEARD P, STEINMANN E, PIETSCHMANN T. Subcellular localization and function of an epitope-tagged p7 in hepatitis C virus-producing cells. **J Virol** 2013, 87, 1664-1678.

MATZ J, KESSIER P, BOUCHET J, COMBES O, RAMOS OH, BARIN F, BATY D, MARTIN L, BENICHOUS S, CHAMES P. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and co-receptor binding sites of HIV-1 gp120. **J Virol** 2013, 87, 1137-1149.

VELTER A, BARIN F, BOUYSSOU A, GUINARD J, LEON L, LE VU S, PILLONEL J, SPIRE B, SEMAILLE C. HIV prevalence and sexual risk behaviors associated with awareness of HIV status among men who have sex with men in Paris, France. **AIDS & Behav** 2013, 17 : 1266-1278.

DESCAMPS D, ASSOUMOU L, CHAIX ML, CHAILLON A, PAKIANATHER S, DE ROUGEMONT A, STORTO A, DOS SANTOS G, KRIVINE A, DELAUGERRE C, MONTES B, IZOPET J, CHARPENTIER C, WIRDEN M, MAILLARD A, MORAND-JOUBERT L, PALLIER C, PLANTIER JC, GUINARD J, TAMALET C, COTTALORDA J, MARCELIN AG, DESBOIS D, HENQUELL C, CALVEZ V, BRUN-VEZINET F, MASQUELIER B, COSTAGLIOLA D. National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade : 2001-2011. **J Antimicrob Chemother** 2013, in press.

SEMAILLE C, BARIN F, BOUYSSOU A, PEYTAVIN G, GUINARD J, LE VU S, PILLONEL J, SPIRE B, VELTER A. High viral loads among HIV-positive MSM attending gay venues : implications for HIV transmission. **J Acquir Immune Defic Syndr** 2013, 63 : e122 - e124.

ESTEBAN-RIESCO L, DEPAULIS F, MOREAU A, BACQ Y, DUBOIS F, GOUDEAU A, GAUDY-GRAFFIN C. Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection. **Virology** 2013, 44 : 90-99.

BRAIBANT M, GONG EY, PLANTIER JC, MOREAU T, ALESSANDRI E, SIMON F, BARIN F. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups. **AIDS**, 2013, 27, 1239-1244.

CONTENTIN L, GUILLOIN A, GAROT D, GAUDY-GRAFFIN C, PERROTIN D. Acute respiratory distress syndrome secondary to human metapneumovirus infection in a young healthy adult. **Intensive Care Med** 2013, 39, 533-534.

BEAUMONT E, ROINGEARD P. Prospects for prophylactic hepatitis C vaccines based on virus-like particles. **Human Vaccin Immunother** 2013, 9, 1-7.

VALLET S, LARRAT S, LAPERCHE S, LE GUILLOU-GUILLEMETTE H, LEGRAND-ABRAVANEL F, BOUCHARDEAU F, PIVERT A, HENQUELL C, MIRAND A, ANDRE-GARNIER E, GIORDANENGO V, LAGATHU G, THIBAUT V, SCHOLTES C, SCHROVER E, GAUDY-GRAFFIN C, MAYLIN S, TRIMOULET P, BROCHOT E, HANTZ S, GOZLAN J, ROQUE-ALFONSO A-M, SOUSSAN P, PLANTIER J-C, CHARPENTIER C, CHEVALIEZ S, COLSON P, MACKIEWICZ V, AGUILERA L, ROSEC S, GOURIOU S, MAGNAT N, LUNEL-FABIANI F, IZOPET J, MORAND P, PAYAN C, PAWLITSKY J-M. Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping. **J Clin Microbiol** 2013, 51, 1428-1433.

KHAMDUANG W, NGO-GIANG-HUONG N, GAUDY-GRAFFIN C, JOURDAI G, SUWANKORNSAKUL W, JARUPANICH T, CHALERMPOLPRAPA V, NANTA S, PUARATTANA-AROONKORN, TONMAT S, LALLEMANT M, GOUDEAU A, SIRIRUNGSI W. Prevalence, risk factors and impact of isolated antibody to hepatitis B core antigen and occult HBV infection in HIV-1 infected pregnant women in Thailand. **Clin Infect Dis** 2013, 56, 1704-1712.

THIBAUT V, GAUDY-GRAFFIN C, COLSON P, GOZLAN J, SCHNEPF N, TRIMOULET P, PALLIER C, SAUNE K, BRANGER M, COSTE M, ROUDOT-THORAVAL F. Epidemiological, virological and clinical characteristics of HBV infection in 233 HIV coinfecting patients : a French multicentre collaborative study. **Virology J** 2013 10:87.

GATAULT P, HALIMI J-M, FORCONI C, THIBAUT G, BARBET C, GAUDY-GRAFFIN C, GOUDEAU A, BRUYERE F, LEBRANCHU Y, BUCHLER M, BARON C. CMV latency in the donor is an independent risk factor of kidney graft loss: impact of full human leukocyte antigen class I mismatch and post-transplantation CD8+-cell attrition. **Am J Transplant** 2013, 13, 2119-2129.

PREL A, SENSEBE L, PAGES JC. Influence of untranslated regions on retroviral mRNA transfer and expression. **BMC Biotechnol** 2013, 13(1):35.

BOUVIN M, MORGAND M, MOREAU A, JESTIN P, SIMONNET P, TRAN L, GOUJARD C, MEYER L, BARIN F, BRAIBANT M. Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. **PLoS Pathogens** 2013, 9, e1003477.

English version



Contact

Inserm - U966 MAVIVH
10 boulevard Tonnellé - BP 3223
37032 Tours Cedex 1 - France
Tél. : 33 (2) 47 36 61 27
Fax : 33 (2) 47 36 61 26

Secrétariat :

E-mail : angelique.masse@univ-tours.fr

Directeur : Philippe ROINGEARD

E-mail : roingear@med.univ-tours.fr

Directeur adjoint : Francis BARIN

E-mail : fbarin@med.univ-tours.fr

Fiches Informations U966

[\[- 0Ko\]](#)

[Fiche Inserm \[- 0Ko\]](#)

[Fiche Université \[- 0Ko\]](#)

Nos partenaires

Institutionnels

Organismes soutenant nos travaux

Autres